ASCO 2016 | INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety results
Elias Jabbour, MD from the The University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of the results of the INO-VATE trial of inotuzumab ozogamicin (InO) for relapsed/refractory acute lymphoblastic leukemia (ALL) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Jabbour explains the mechanism of action inotuzumab ozogamicin, which is a monoclonal antibody that targets CD22 and the design of the INO-VATE trial (NCT01564784), which is a randomized Phase III trial. Patients received either standard of care or inotuzumab and the primary endpoint was response to therapy and overall survival (OS). Complete response was approximately 80% and, according to Dr Jabbour, those patients who responded, further showed high rates of minimal residual disease (MRD) negativity. According to Dr Jabbour, the efficacy and safety profile of the drug is good for younger and older patients and he further discusses the future use of the drug.
Get great new content delivered to your inboxSign up